BeiGene gears up for cancer immunology debut
This article was originally published in Scrip
Executive Summary
After readying three drug candidates for clinical testing, securing first round financing and obtaining milestone payments from Merck Serono, Chinese biotech firm BeiGene has unveiled an exciting cancer immunology pipeline and a potential listing on the NASDAQ.